According to Zhitong Finance APP, Innovent Biologics (01801) rose over 2%, up 1.68% as of press time to HK$84.9, with turnover of HK$255 million.
On the news front, Johnson & Johnson recently announced the acquisition of Ollin Biosciences for US$2.2 billion in upfront payment, plus up to approximately US$1.125 billion in regulatory and commercial milestone payments, bringing the total transaction value to as much as US$3.325 billion.
UBS noted that Innovent Biologics' partner Ollin will be acquired by Johnson & Johnson, and the core Phase III asset IBI/OLN324 (Ang2/VEGF) will be incorporated into Johnson & Johnson's pipeline. UBS holds a positive view on this.
UBS believes the deal affirms Innovent Biologics' strength in ophthalmology R&D, including the US$2.2 billion upfront payment and up to US$1.125 billion in milestone payments. The Phase 1b clinical data for IBI/OLN324 in wAMD/DME is positive relative to faricimab. Blackstone will pay Johnson & Johnson US$750 million to fully fund the Phase III clinical trial of OLN324, in exchange for certain milestones and single-digit royalties.
Comments